NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis $320.61 +0.08 (+0.02%) Closing price 04:00 PM EasternExtended Trading$320.68 +0.06 (+0.02%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Praxis Precision Medicines Stock (NASDAQ:PRAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PRAX alerts:Sign Up Key Stats Today's Range$306.79▼$325.8950-Day Range$276.44▼$346.1952-Week Range$35.21▼$358.76Volume300,531 shsAverage Volume456,373 shsMarket Capitalization$8.94 billionP/E RatioN/ADividend YieldN/APrice Target$592.67Consensus RatingModerate Buy Company Overview Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders. The company’s pipeline includes several lead candidates at various stages of development. PRAX-562 is a selective persistent sodium current inhibitor being evaluated for severe epilepsies and other hyperexcitability disorders. PRAX-944, a T-type calcium channel blocker, is under investigation for essential tremor. PRAX-114, a neuroactive steroid that modulates GABAA receptors, is in development for major depressive disorder and postpartum depression. Additional programs, such as PRAX-330 and early research efforts targeting novel ion channel subtypes, further expand the company’s therapeutic reach. Founded in 2015 and headquartered in Boston, Massachusetts, Praxis Precision Medicines conducts preclinical and clinical research primarily in the United States, with clinical trial sites across North America and Europe. The company has built a platform that integrates genetic discovery, patient stratification and biomarker development to accelerate the translation of scientific findings into targeted treatments. By collaborating with academic institutions and leveraging external partnerships, Praxis aims to optimize its clinical strategy and deliver data-driven insights for regulatory interactions. Leadership at Praxis includes Winston W. Yen, M.D., co-founder and Chief Executive Officer, who brings experience in neuroscience drug development, and a management team with expertise spanning medicinal chemistry, clinical development and regulatory affairs. The company’s governance and scientific advisory board feature experts in neurology, genetics and drug discovery, supporting a strategy focused on precision medicine for CNS diseases.AI Generated. May Contain Errors. Read More Praxis Precision Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScorePRAX MarketRank™: Praxis Precision Medicines scored higher than 63% of companies evaluated by MarketBeat, and ranked 279th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 4 strong buy ratings, 13 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialPraxis Precision Medicines has a consensus price target of $592.67, representing about 84.5% upside from its current price of $321.28.Amount of Analyst CoveragePraxis Precision Medicines has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Praxis Precision Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Praxis Precision Medicines are expected to grow in the coming year, from ($14.79) to ($10.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -24.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -24.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 9.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Praxis Precision Medicines' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.92% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 9.35.Change versus previous monthShort interest in Praxis Precision Medicines has recently decreased by 0.10%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.05 News SentimentPraxis Precision Medicines has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Praxis Precision Medicines this week, compared to 7 articles on an average week.Search Interest10 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows5 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by Insiders2.70% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Praxis Precision Medicines' insider trading history. Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRAX Stock News HeadlinesPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by BrokeragesMay 19 at 2:22 AM | americanbankingnews.comIs FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)?May 18 at 9:58 AM | finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 19 at 1:00 AM | Profits Run (Ad)Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $715.00 at Truist FinancialMay 14, 2026 | americanbankingnews.comPraxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comWedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)May 11, 2026 | insidermonkey.comHC Wainwright Has Negative Outlook of PRAX FY2030 EarningsMay 11, 2026 | americanbankingnews.comBTIG Research Reiterates "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX)May 10, 2026 | americanbankingnews.comSee More Headlines PRAX Stock Analysis - Frequently Asked Questions How have PRAX shares performed this year? Praxis Precision Medicines' stock was trading at $294.74 on January 1st, 2026. Since then, PRAX stock has increased by 9.0% and is now trading at $321.2830. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its quarterly earnings results on Thursday, May, 7th. The company reported ($3.20) earnings per share for the quarter, topping the consensus estimate of ($3.58) by $0.38. Read the conference call transcript. When did Praxis Precision Medicines' stock split? Praxis Precision Medicines's stock reverse split on the morning of Wednesday, November 29th 2023.The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $170 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Praxis Precision Medicines' top institutional shareholders include Janus Henderson Group PLC (12.41%), Bank of America Corp DE (1.92%), Pictet Asset Management Holding SA (1.03%) and Orbimed Advisors LLC (0.62%). Insiders that own company stock include Alex Nemiroff, Lauren Mastrocola, Marcio Souza and Jill Desimone. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Praxis Precision Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Praxis Precision Medicines investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today5/19/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PRAX's financial health is in the Green zone, according to TradeSmith. PRAX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRAX CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees110Year Founded2015Price Target and Rating Average Price Target for Praxis Precision Medicines$592.67 High Price Target$1,245.00 Low Price Target$83.00 Potential Upside/Downside+84.9%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($13.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$303.27 million Net MarginsN/A Pretax Margin-3,658.53% Return on Equity-43.02% Return on Assets-40.22% Debt Debt-to-Equity RatioN/A Current Ratio15.88 Quick Ratio15.88 Sales & Book Value Annual Sales$8.55 million Price / Sales1,045.45 Cash FlowN/A Price / Cash FlowN/A Book Value$34.85 per share Price / Book9.20Miscellaneous Outstanding Shares27,880,000Free Float27,126,000Market Cap$8.94 billion OptionableOptionable Beta2.76 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:PRAX) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
